Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company's TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TTPH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.96
  • 50 Day Moving Average: $3.74
  • 200 Day Moving Average: $4.23
  • 52-Week Range: $3.12 - $12.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.82
  • P/E Growth: -0.01
  • Market Cap: $146.79M
  • Outstanding Shares: 36,698,000
  • Beta: 2.61
  • Net Margins: -821.25%
  • Return on Equity: -35.43%
  • Return on Assets: -33.62%
  • Current Ratio: 18.04%
  • Quick Ratio: 18.04%
Additional Links:
Companies Related to Tetraphase Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $10.00 (152.53% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateFirmActionRatingPrice TargetDetails
8/5/2016WedbushReiterated RatingNeutral$4.00View Rating Details
5/16/2016GabelliReiterated RatingNeutralView Rating Details
5/14/2016Needham & Company LLCReiterated RatingHoldView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageMarket Perform$8.00View Rating Details
11/19/2015SunTrust Banks Inc.UpgradeNeutral -> Buy$12.00 -> $21.00View Rating Details
9/9/2015GuggenheimLower Price TargetBuy$60.00 -> $20.00View Rating Details
9/9/2015Robert W. BairdDowngradeOutperform -> Neutral$41.00 -> $10.00View Rating Details
9/9/2015Cantor FitzgeraldDowngradeBuy -> Hold$50.00 -> $11.00View Rating Details
9/9/2015NomuraDowngradeBuy -> Neutral$54.00 -> $10.00View Rating Details
9/9/2015Stifel NicolausDowngradeBuy -> Hold$57.00View Rating Details
9/9/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
9/9/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)ViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Current Year EPS Consensus Estimate: $-1.96 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.41)($0.44)
Q2 20162($0.48)($0.44)($0.46)
Q3 20162($0.49)($0.47)($0.48)
Q4 20162($0.56)($0.47)($0.52)
Q1 20171($0.56)($0.56)($0.56)
Q2 20171($0.58)($0.58)($0.58)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)


Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 59.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
News IconEarnings According to Analysts for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)? - CSZ News (NASDAQ:TTPH)
cincysportszone.com - October 19 at 8:55 AM
News IconThe Key Numbers To Watch From Tetraphase Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:TTPH)
voiceregistrar.com - October 18 at 7:39 PM
News IconUpgrades And Downgrades For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - NewsDen (NASDAQ:TTPH)
newsden.net - October 17 at 7:42 PM
rttnews.com logoBe All Ears For ABEO, Lucentis PFS Gets FDA Nod, XOMA Effects Stock Split - RTT News (NASDAQ:TTPH)
www.rttnews.com - October 17 at 8:49 AM
News IconTetraphase Pharmaceuticals Doses First Patient In IGNITE4 Phase 3 Clinical Trial Of Eravacycline In cIAI - Clinical Leader (NASDAQ:TTPH)
www.clinicalleader.com - October 17 at 8:49 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Latest Broker Coverage - NewsDen (NASDAQ:TTPH)
newsden.net - October 16 at 8:59 AM
directorstalkinterviews.com logoTetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI - DirectorsTalk Interviews (NASDAQ:TTPH)
www.directorstalkinterviews.com - October 15 at 7:20 PM
streetinsider.com logoTetraphase Pharma (TTPH) Announces Dosing of First IGNITE4 Phase 3 Patient (NASDAQ:TTPH)
www.streetinsider.com - October 14 at 7:38 PM
News IconRating Sentiment Summary: Discussion stirs around Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) this week; here ... - MoneyMakingArticles (NASDAQ:TTPH)
www.mmahotstuff.com - October 14 at 11:09 AM
streetinsider.com logoTetraphase Pharma (TTPH) Announces Dosing of First IGNITE4 Phase 3 Patient - StreetInsider.com (NASDAQ:TTPH)
www.streetinsider.com - October 14 at 11:09 AM
publicnow.com logoTetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI (NASDAQ:TTPH)
www.publicnow.com - October 14 at 11:09 AM
investornewswire.com logoTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Posts EPS Of ... - Investor Newswire (NASDAQ:TTPH)
www.investornewswire.com - October 12 at 12:44 PM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Shares - CSZ News (NASDAQ:TTPH)
cincysportszone.com - October 12 at 12:44 PM
capitalcube.com logoETF’s with exposure to Tetraphase Pharmaceuticals, Inc. : October 11, 2016 (NASDAQ:TTPH)
www.capitalcube.com - October 11 at 7:34 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NASDAQ:TTPH)
voiceregistrar.com - October 6 at 7:33 PM
News IconSell-side Review & Stock Update on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Recall News (NASDAQ:TTPH)
www.automobile-recalls.net - October 6 at 8:58 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Latest Broker Views - NewsDen (NASDAQ:TTPH)
newsden.net - October 6 at 8:58 AM
News IconAnalyst Review: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - NewsDen (NASDAQ:TTPH)
newsden.net - September 28 at 8:53 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Frisco Fastball (NASDAQ:TTPH)
friscofastball.com - September 13 at 8:50 AM
capitalcube.com logoETF’s with exposure to Tetraphase Pharmaceuticals, Inc. : September 7, 2016 (NASDAQ:TTPH)
www.capitalcube.com - September 7 at 11:40 AM
capitalcube.com logoETF’s with exposure to Tetraphase Pharmaceuticals, Inc. : August 25, 2016 (NASDAQ:TTPH)
www.capitalcube.com - August 25 at 8:12 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Company In Focus: Analysts & Crowd Weigh in - Post News (NASDAQ:TTPH)
www.kentuckypostnews.com - August 24 at 7:40 PM
News IconStock Tracking Lower for the Quarter: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Post News (NASDAQ:TTPH)
www.kentuckypostnews.com - August 20 at 7:27 PM
News IconIs it Time to Buy Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)? Crowd & Analysts Weigh in - Post News (NASDAQ:TTPH)
www.kentuckypostnews.com - August 17 at 8:15 PM
investornewswire.com logoWill Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Surprise This Quarter? - Investor Newswire (NASDAQ:TTPH)
www.investornewswire.com - August 14 at 8:36 AM
finance.yahoo.com - August 12 at 8:04 PM
capitalcube.com logoTetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:TTPH)
www.capitalcube.com - August 12 at 11:11 AM
globenewswire.com logoTetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:TTPH)
globenewswire.com - August 8 at 8:37 AM
stockhouse.com logoTetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress (NASDAQ:TTPH)
www.stockhouse.com - August 5 at 8:10 PM
sg.finance.yahoo.com logoTetraphase reports 2Q loss (NASDAQ:TTPH)
sg.finance.yahoo.com - August 5 at 11:00 AM
ftsenews.co.uk logoTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Updated Price ... - FTSE News (NASDAQ:TTPH)
www.ftsenews.co.uk - August 4 at 11:12 AM
streetinsider.com logoTetraphase Pharma (TTPH) Commences Dosing in TP-6076 Phase ... - StreetInsider.com (NASDAQ:TTPH)
www.streetinsider.com - August 2 at 8:53 AM
News IconTop Earnings to Watch for: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - The Voice Registrar (NASDAQ:TTPH)
voiceregistrar.com - August 2 at 8:53 AM
finance.yahoo.com logo8:02 am Tetraphase Pharmaceuticals initiates patient dosing in a phase 1 clinical trial for intravenous TP-6076 (NASDAQ:TTPH)
finance.yahoo.com - August 1 at 8:02 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria (NASDAQ:TTPH)
finance.yahoo.com - August 1 at 8:00 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - July 23 at 11:44 AM
News IconTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Sellers Covered 19.37% of Their Shorts - Consumer Eagle (NASDAQ:TTPH)
www.consumereagle.com - July 23 at 11:44 AM
equities.com logoTetraphase Pharmaceuticals Inc. (TTPH) Drops 5.73% on July 19 - Equities.com (NASDAQ:TTPH)
www.equities.com - July 20 at 9:00 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:TTPH)
telanaganapress.com - July 13 at 10:49 AM
News IconHow Analysts Rated Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Last Week? - Consumer Eagle (NASDAQ:TTPH)
www.consumereagle.com - July 13 at 10:49 AM
News IconStock Rating Watch and Earnings Insight for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Press Telegraph (NASDAQ:TTPH)
presstelegraph.com - July 11 at 8:55 AM
News IconTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Short Interest Decreased By 11.01% - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - July 8 at 10:47 AM
News IconCan Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - July 8 at 10:47 AM
News IconCompany Stock Focus for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Which Way Will Shares Head? - Press Telegraph (NASDAQ:TTPH)
presstelegraph.com - July 8 at 10:47 AM
News IconHeightened Volatility Check on: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - July 7 at 8:02 PM
News IconShare Performance Recap for: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Press Telegraph (NASDAQ:TTPH)
presstelegraph.com - July 4 at 6:54 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - July 1 at 10:35 AM
News IconAre Analysts Bullish Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) After Last Week? - Engelwood Daily (NASDAQ:TTPH)
www.engelwooddaily.com - June 30 at 8:05 PM
News IconStock under Analysts' radar: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - News Oracle (NASDAQ:TTPH)
www.newsoracle.com - June 30 at 8:05 PM
4-traders.com logoTetraphase Pharmaceuticals : Added to the Russell Microcap Index (NASDAQ:TTPH)
www.4-traders.com - June 29 at 7:51 PM


Tetraphase Pharmaceuticals (NASDAQ:TTPH) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by MarketBeat.com Staff